Trastuzumab not for ductal carcinoma in situ?

Zeina Nahleh, Azadeh Namakydoust, Rania Bakkar, John W Bishop

Research output: Contribution to journalArticlepeer-review


Ductal carcinoma in situ (DCIS) is a preinvasive breast lesion accounting for approximately 30% of all newly detected breast cancers in the US. DCIS has been separated into two groups by architecture (comedo versus noncomedo) and nuclear grade. The expression of biological markers in DCIS, however, would reflect the true biologic potential of the lesion. Patients with estrogen receptor (ER)-negative, human epidermal growth factor-2 (HER-2)-positive DCIS pose a treatment challenge. They are not candidates for tamoxifen; trastuzumab has an undetermined role in DCIS. In this report, we present a case of a 45-year-old woman diagnosed with invasive breast cancer and ER-negative/HER-2- positive DCIS who developed recurrence and progression of DCIS as manifested by a new palpable mass while receiving trastuzumab as part of adjuvant treatment for invasive breast cancer. The potential clinical implications are discussed.

Original languageEnglish (US)
Pages (from-to)1231-1235
Number of pages5
JournalAnti-Cancer Drugs
Issue number10
StatePublished - Nov 2007
Externally publishedYes


  • Ductal carcinoma in situ
  • Trastuzumab

ASJC Scopus subject areas

  • Pharmacology
  • Cancer Research
  • Oncology


Dive into the research topics of 'Trastuzumab not for ductal carcinoma in situ?'. Together they form a unique fingerprint.

Cite this